We describe a patient who initially presented with a mixed thymic tumor and developed myasthenia gravis 8 years following thymectomy with recurrence of metastatic disease. Metastasis to the pleura, mediastinum, and cervical spine was identified with a positron emission tomography scan when this patient presented with recurring pneumonias and atrial fibrillation. The presentation and diagnosis were clouded by multiple courses of prednisone and chemotherapy for respiratory complications and metastatic disease, respectively. Classical myasthenia gravis symptoms emerged when his prednisone was tapered. The delayed presentation of paraneoplastic disease and the rare metastatic site make this case particularly unusual. M yasthenia gravis (MG) is an autoimmune disorder in which the neuromuscular junction is targeted most commonly by autoantibodies to postsynaptic acetylcholine receptors (AchR-Ab) (1) . Eighty percent of patients with MG have IgG-type antibodies against AchR, while AchR-Ab-negative MG cases tend to have a more severe manifestation of disease with other autoantibodies (i.e., musclespecifi c tyrosine kinase antibodies) (2) . Th ymomas are reported in 10% to 15% of patients with MG (1, 3) . MG is even rarer in association with thymic carcinoma, with ∼1% of thymic carcinoma patients exhibiting MG symptoms (4).
CASE DESCRIPTION
A 44-year-old man initially presented at age 34 (2006) with fatigue, chest pain, and severe dyspnea on exertion. A chest computed tomography scan revealed a thymic mass with invasion of local structures. He underwent a left second interspace mediastinotomy with frozen section, which showed a thymic tumor with features ranging from thymoma to malignant thymoma with areas of thymic carcinoma with squamous diff erentiation. Th e thymoma component had a type B3 pattern. Given the frozen section diagnosis, he underwent a median sternotomy with radical excision, including removal of a major portion of the pericardium due to tumor invasion. Surgery was complicated with left vocal cord paralysis and brachiocephalic vein thrombosis. He underwent postoperative radiation therapy with concurrent cisplatin/VP-16 chemotherapy. At that time, the patient did not have any signs or symptoms of MG. Due to hoarseness of his voice and frequent aspiration and choking episodes, he required Silastic medialization thyroplasty the same year and revision thyroplasty 6 months later with mild relief.
In 2014, at the age of 42, the patient started complaining of headache, for which he saw a neurologist. Brain magnetic resonance imaging was negative for metastasis, but he had a positive AchR-Ab even though he was asymptomatic. Th at same year, the patient also had frequent hospitalizations for pneumonia and symptomatic paroxysmal atrial fi brillation. Positron emission tomography scan showed hypermetabolic masses in the mediastinum, right lower lobe lung, and C7 vertebra. Biopsy of the mediastinal mass showed recurrent thymic tumor, type B3, without evidence of carcinoma or squamous diff erentiation (Figure 1 ). He received three cycles of carboplatin/taxol, and during this time, he developed an erythematous rash for which he received methylprednisolone. After his third cycle of chemotherapy, he was placed on prednisone for respiratory symptoms. When prednisone was being tapered, the patient started to experience double vision and cervical paraspinal weakness to the extent that he was unable to lift his head. Subsequently, he developed extremity weakness and dyspnea. AchR blocking antibody was positive (29.2 nmol/L; positive if >0.02 nmol/L). His symptoms improved on steroids, pyridostigmine, and fi ve sessions of plasmapheresis. His symptoms are now controlled with azathioprine, pyridostigmine, and low-dose prednisone.
DISCUSSION
Th ymic tumors are rare anterior mediastinal tumors arising from thymic tissue that may be benign or malignant. Th ey account for 20% of anterior mediastinal neoplasms in adults, with an incidence of 0.15 per 100,000 person-years (5) . Th e World Health Organization classifi cation distinguishes between subtypes of thymoma (subtype type A, AB, B1, B2, B3) and thymic carcinoma (type C) depending on histologic appearance (6). Th ymic carcinoma accounts for 5% of thymic malignancies and
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Hourossadat Hashemi Jazi, MD, David M. Harmon, BS, Tuan Tran, MD, and Claude Denham, MD exhibits aggressive clinical behavior, atypical cytology, and poor prognosis (5) . Both thymoma and thymic carcinoma may invade surrounding tissue such as the mediastinum, pericardium, and pleura. Th e main distinction between thymoma and thymic carcinoma is the histologic atypia seen in thymic carcinoma, which can demonstrate multiple histologic cell types (7) . When a thymoma behaves aggressively with invasion, it is sometimes termed malignant (or invasive) thymoma (6) . A small biopsy cannot adequately demonstrate the mixed histology that can be present. Metastasis from thymic tumors is most commonly seen in lymph nodes, liver, and soft tissue/skeletal muscles, with other sites including bone, brain, and abdominal wall (8) (9) (10) (11) .
Th ymic neoplasms can be associated with various paraneoplastic syndromes including MG (7) . Common symptoms associated with MG are diplopia, extraocular muscle weakness, ptosis, limb weakness, and, in severe cases, respiratory distress (2, 3). Five subtypes of MG have been characterized: ocular, hyperplastic thymus, thymoma associated, AchR-Ab negative, and AchR-Ab positive without thymic abnormalities (1). Rare extrathoracic metastases of malignant thymoma (e.g., liver, bone) have also been associated with a few cases of MG (9) (10) (11) .
In patients with thymoma-associated MG, thymectomy in conjunction with acetylcholinesterase inhibitors (such as pyridostigmine) usually results in minimal manifestation of MG symptoms (12) . Recent studies suggest that thymic carcinoma patients with paraneoplastic MG have a signifi cantly better prognosis of cancer survival (13) . Th ese patients' increased survival is likely due to higher resection rates from smaller size and earlier stage of the primary tumor (13) .
Our patient's presentation of MG was interesting, as he did not have symptoms of MG when he had the primary thymic cancer in 2006. After thymectomy, recurrence and metastasis of his malignant thymoma were accompanied by MG symptoms. A classical presentation of MG was seen when tapering steroids for rash and respiratory complaints, which could have masked MG symptoms. It was interesting that the patient developed MG symptoms when his underlying cancer was responding to chemotherapy. Most of the metastases are to the lymph nodes, liver, and soft tissue/skeletal muscles, and this patient's metastasis to the C7 vertebra was unusual.
Plasmapheresis or intravenous immunoglobulin can be benefi cial for severe symptoms of MG (14) . Our patient showed drastic symptomatic improvement after undergoing fi ve rounds of plasmapheresis. Moderate MG symptom improvement has been reported with removal of thymic carcinoma metastases to the pleura (8) . Unfortunately, our patient was not a surgical candidate due to multiple extrathoracic metastases. 
